Bone Marrow Transplant Market Size, Trends, Shares, Insights and Forecast – 2019-2027.

 

image

Statistics:

The global Bone Marrow Transplant Market is estimated to account for US$ 9,535.6 Mn in terms of value and 87,855 procedures in terms of volume by the end of 2019 Global Bone Marrow Transplant Market: Drivers Increasing prevalence of sickle cell anemia, thalassemia, and leukemia is expected to boost growth of the global bone marrow transplant market over the forecast period. For instance, according to stats published in National Center for Biotechnology Information (NCBI) bookshelf in January 2019, the population of sickle cell anemia is approximately 100,000 in the U.S. and is likely to increase.

Hematopoietic and mesenchymal stem cells are the two types of stem cells in bone marrow. Hematopoietic stem cells (HSCs) give rise to other blood cells, in a process called as hematopoiesis. Mesenchymal stem cells are multipotent stromal cells that can differentiate into a several other cell types such as osteoblasts and adipocytes. Bone marrow transplant is used in the treatment of several diseases such as myelodysplastic syndrome, myeloproliferative neoplasms, aplastic anemia, sickle cell anemia, thalassemia, and leukemia.

Global Bone Marrow Transplant Market:

 Restraints Low availability of human leukocyte antigen (HLA) matched bone marrow donor is expected to hinder growth of the global bone marrow transplant market over the forecast period.

Key Takeaways:

The Leukemia treatment segment in the global bone marrow transplant market was valued at US$ 2,382.60 Mn in 2018 and is expected to reach US$ 3,260.5 Mn by 2027 at a CAGR of 3.5% during the forecast period.      

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/bone-marrow-transplant-market-232

 Increasing incidence and prevalence of leukemia in developed and developing economies is anticipated to assist the growth of the segment during the forecast period. The hospitals segment held dominant position in the global bone marrow transplant market in 2018, accounting for 92.8% share in terms of value, followed by multi-speciality clinics respectively. Increasing patient population along with increasing healthcare expenditure in developing economies is anticipated to assist the growth of the segment during the forecast period Market Trends Increasing funding for R&D in stem cell therapy is expected to boost growth of the market.

For instance, in December 2019, California Institute for Regenerative Medicine granted over US$ 18 million to University of California, Los Angeles to develop and conduct clinical trials for stem-cell-based treatments. Increasing R&D in bone marrow is also expected to propel growth of the market. For instance, in August 2019, researchers from Monash University demonstrated that osteopontin, a protein that in humans is encoded by the SPP1 gene, is also required for fetal hematopoiesis in maintaining the hematopoietic stem cells and progenitor pool in fetal bone marrow.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/232

Global Bone Marrow Transplant Market:

Competitive Landscape Major players operating in the global bone marrow transplant market include, Lonza Group Ltd., Merck Millipore Corporation, Sanofi-Aventis LLC, AllCells LLC, STEMCELL Technologies, and American Type Culture Collection (ATCC) Inc. Key Developments In December 2019, Forty Seven Inc. announced preclinical proof-of-concept data for its novel all antibody conditioning regimen, comprised of FSI-174, its anti-cKIT antibody, and magrolimab, its anti-CD47 antibody.

The study proved that the combination of FSI-174 and magrolimab significantly decreased hematopoietic stem cells from the bone marrow without any dose limiting toxicities. In December 2019, Sangamo Therapeutics Inc. announced preliminary results from the first three patients treated in the Phase 1/2 THALES study that assessed ST-400 ex vivo gene-edited cell therapy in transfusion-dependent beta thalassemia.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/232

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:[email protected]

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737